Zeitschrift für Gastroenterologie
-
Case Reports
Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure.
In recent years, immune checkpoint inhibitors (ICIs) were successfully introduced to cancer therapy, and these drugs have already become essential for the treatment of various noncurable tumors. However, monotherapy in advanced hepatocellular carcinoma (aHCC) failed to show statistically significant improvement. ⋯ However, it remains unclear if failure to monotherapy has an impact on combination therapy. We therefore report a patient well responding to combination therapy despite previous failures to TKI and ICI monotherapy.